Alzheimer's Disease News and Research RSS Feed - Alzheimer's Disease News and Research Twitter

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
AAN urges for more research on use of medical marijuana for brain, nervous system disorders

AAN urges for more research on use of medical marijuana for brain, nervous system disorders

The American Academy of Neurology is calling for more research on the use of medical marijuana for brain, spine and nervous system disorders in a new position statement released by the AAN, the world's largest association of neurologists with more than 28,000 members. [More]
Loyola neurologist finds little scientific evidence that brain games improve cognitive function

Loyola neurologist finds little scientific evidence that brain games improve cognitive function

Computerized brain games that are advertised as a way to help boost intelligence and prevent dementia will be popular Christmas gifts this year. [More]
Migraine headache may double risk of nervous system condition that causes Bell's palsy

Migraine headache may double risk of nervous system condition that causes Bell's palsy

Migraine headache may double the risk of a nervous system condition that causes facial paralysis, called Bell's palsy, according to a new study published in the December 17, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology. [More]
Novel technique to identify biological markers in brain development

Novel technique to identify biological markers in brain development

With a unique, multi-faceted approach, researchers at the Lieber Institute for Brain Development have quantified the effect of previously unidentified anomalies in genetic expression that determine how the human brain develops from its earliest stages. [More]
ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

Molecular Medicine, a peer-reviewed biomedical journal published by the Feinstein Institute Press, published the results of a new study reporting clinically significant pain reduction in type 2 diabetic patients. In an exploratory study conducted by Araim Pharmaceuticals, a biotech company developing novel treatments for chronic diseases, investigators also observed improvements in metabolic control in patients administered ARA 290. [More]
UT Southwestern researchers identify cell signaling mechanism that plays vital role in brain cancer

UT Southwestern researchers identify cell signaling mechanism that plays vital role in brain cancer

UT Southwestern Medical Center neurology researchers have identified an important cell signaling mechanism that plays an important role in brain cancer and may provide a new therapeutic target. [More]
Anavex Life Sciences qualifies to trade on OTCQX

Anavex Life Sciences qualifies to trade on OTCQX

OTC Markets Group Inc., operator of Open, Transparent and Connected financial marketplaces, today announced that Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS), and various types of cancer, has qualified to trade on OTCQX, the best marketplace for established, global and growth companies. [More]
UAB neurologist creates clinic to offer personalized Alzheimer's risk assessment service

UAB neurologist creates clinic to offer personalized Alzheimer's risk assessment service

Neurologist David Geldmacher, M.D., who leads the University of Alabama at Birmingham Division of Memory Disorders, sees many older patients with memory loss, dementia or Alzheimer's disease. He also sees their caregivers, who often are spouses or adult children. [More]
New study finds that poor sleep may lead to dementia

New study finds that poor sleep may lead to dementia

People who have sleep apnea or spend less time in deep sleep may be more likely to have changes in the brain that are associated with dementia, according to a new study published in the December 10, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Researchers gain new insights into potential treatment for Alzheimer's disease

Researchers gain new insights into potential treatment for Alzheimer's disease

It is estimated that about 35 million people worldwide currently suffer from dementia and it is expected that the number will increase to 135 million by the year 2050. The disease is already one of the most common health problems in the elderly, which is why experts predict that the numbers of people affected will increase over time. [More]
BUSM's Carmela Abraham receives 2014 Massachusetts Neuroscience Consortium Award

BUSM's Carmela Abraham receives 2014 Massachusetts Neuroscience Consortium Award

Carmela Abraham, PhD, professor of biochemistry and pharmacology at Boston University School of Medicine, was one of six recipients of this year's Massachusetts Neuroscience Consortium Award out of nearly 60 applicants. The grant was awarded to her for her work on multiple sclerosis and the role of the life extension protein Klotho in the limited repair of white matter in the disease. [More]
MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys AG and Xencor Inc. today announced the publication of final results of a Phase 1/2a trial evaluating MOR208 (formerly XmAb5574) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). [More]
Study suggests Golgi as potential drug target for Alzheimer's treatment

Study suggests Golgi as potential drug target for Alzheimer's treatment

Alzheimer's disease (AD) progresses inside the brain in a rising storm of cellular chaos as deposits of the toxic protein, amyloid-beta (Aβ), overwhelm neurons. An apparent side effect of accumulating Aβ in neurons is the fragmentation of the Golgi apparatus, the part of the cell involved in packaging and sorting protein cargo including the precursor of Aβ. But is the destruction the Golgi a kind of collateral damage from the Aβ storm or is the loss of Golgi function itself part of the driving force behind Alzheimer's? This was the question for Yanzhuang Wang, Gunjan Joshi, and colleagues at the University of Michigan, Ann Arbor, as they set out to uncover the mechanism damaging the Golgi, using a transgenic mouse and tissue culture models of AD to look at what was going on. [More]

Landmark call for neurodegenerative disease research

The EU Joint Programme - Neurodegenerative Disease Research has announced a EUR 30 million call for neurodegenerative disease research topped-up with EUR 10 million from the Horizon 2020 framework programme for research and innovation of the European Union. [More]
UAB research suggests potential therapeutic target for patients with frontotemporal dementia

UAB research suggests potential therapeutic target for patients with frontotemporal dementia

Drugs that boost the function of a specific type of neurotransmitter receptor may provide benefit to patients with the second most common type of dementia, according to research by scientists at the University of Alabama at Birmingham published today in the Journal of Neuroscience. [More]
Ten facts about Alzheimer's disease

Ten facts about Alzheimer's disease

Dr. Daniel Thomas will be conducting a ground-breaking study to determine if cognitive decline due to memory-destroying Alzheimer's disease can begin to be reversed in 90 days by combating the root causes using an innovative combination of diet, exercise, vitamin supplements, hormone therapy, and intravenous nutrition. [More]
Researchers use MRI techniques to study consequences of anorexia nervosa on brain structure

Researchers use MRI techniques to study consequences of anorexia nervosa on brain structure

Researchers from the Translational Developmental Neuroscience Lab led by Professor Stefan Ehrlich at the Department of Child and Adolescent Psychiatry and Psychotherapy of the University Hospital Carl Gustav Carus at the TU Dresden (Faculty of Medicine) used state-of-the-art magnetic resonance imaging (MRI) techniques to investigate the consequences of anorexia nervosa on brain structure. [More]
Experts report three key topics that may make difference in the battle against Alzheimer's disease

Experts report three key topics that may make difference in the battle against Alzheimer's disease

Detection, prevention, and preclinical treatment are three key areas that may make a difference in the battle to reduce the rapid rise of new Alzheimer's disease (AD) cases every year. These three topics are the focus of an important new supplement to the Journal of Alzheimer's Disease. [More]
Neuroimaging markers have synergistic effect on cognitive decline

Neuroimaging markers have synergistic effect on cognitive decline

The Alzheimer disease neuroimaging markers β-amyloid and neurodegeneration have synergistic effects on the rate of cognitive decline in clinically normal people, research shows. [More]
Johns Hopkins School of Nursing launches free online course on dementia

Johns Hopkins School of Nursing launches free online course on dementia

Pick a holiday - any holiday - at this time of year, and thoughts turn to family, of bringing the generations together to re-live memories and make new ones. [More]